Literature DB >> 24598798

SHIP-1 deficiency in the myeloid compartment is insufficient to induce myeloid expansion or chronic inflammation.

M J Maxwell1, N Srivastava2, M-Y Park2, E Tsantikos1, R W Engelman3, W G Kerr4, M L Hibbs1.   

Abstract

SHIP-1 has an important role in controlling immune cell function through its ability to downmodulate PI3K signaling pathways that regulate cell survival and responses to stimulation. Mice deficient in SHIP-1 display several chronic inflammatory phenotypes including antibody-mediated autoimmune disease, Crohn's disease-like ileitis and a lung disease reminiscent of chronic obstructive pulmonary disease. The ileum and lungs of SHIP-1-deficient mice are infiltrated at an early age with abundant myeloid cells and the mice have a limited lifespan primarily thought to be due to the consolidation of lungs with spontaneously activated macrophages. To determine whether the myeloid compartment is the key initiator of inflammatory disease in SHIP-1-deficient mice, we examined two independent strains of mice harboring myeloid-restricted deletion of SHIP-1. Contrary to expectations, conditional deletion of SHIP-1 in myeloid cells did not result in consolidating pneumonia or segmental ileitis typical of germline SHIP-1 deficiency. In addition, other myeloid cell abnormalities characteristic of germline loss of SHIP-1, including flagrant splenomegaly and enhanced myelopoiesis, were absent in mice lacking SHIP-1 in myeloid cells. This study indicates that the spontaneous inflammatory disease characteristic of germline SHIP-1 deficiency is not initiated solely by LysM-positive myeloid cells but requires the simultaneous loss of SHIP-1 in other hematolymphoid lineages.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24598798     DOI: 10.1038/gene.2014.9

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  45 in total

1.  Cutting edge: dominance by an MHC-independent inhibitory receptor compromises NK killing of complex targets.

Authors:  Joseph A Wahle; Kim H T Paraiso; Amy L Costello; Emily L Goll; Charles L Sentman; William G Kerr
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

Review 2.  Taming the PI3K team to hold inflammation and cancer at bay.

Authors:  Emilio Hirsch; Elisa Ciraolo; Alessandra Ghigo; Carlotta Costa
Journal:  Pharmacol Ther       Date:  2008-03-05       Impact factor: 12.310

3.  Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses.

Authors:  A M Oliver; F Martin; G L Gartland; R H Carter; J F Kearney
Journal:  Eur J Immunol       Date:  1997-09       Impact factor: 5.532

4.  Genetic segregation of inflammatory lung disease and autoimmune disease severity in SHIP-1-/- mice.

Authors:  Mhairi J Maxwell; Mubing Duan; Jane E Armes; Gary P Anderson; David M Tarlinton; Margaret L Hibbs
Journal:  J Immunol       Date:  2011-05-13       Impact factor: 5.422

5.  SHIP-deficient mice develop spontaneous intestinal inflammation and arginase-dependent fibrosis.

Authors:  Keith W McLarren; Alexandra E Cole; Shelley B Weisser; Nicole S Voglmaier; Victoria S Conlin; Kevan Jacobson; Oana Popescu; Jean-Luc Boucher; Laura M Sly
Journal:  Am J Pathol       Date:  2011-05-07       Impact factor: 4.307

6.  SHIP1 inhibition increases immunoregulatory capacity and triggers apoptosis of hematopoietic cancer cells.

Authors:  Robert Brooks; Gwenny M Fuhler; Sonia Iyer; Michelle J Smith; Mi-Young Park; Kim H T Paraiso; Robert W Engelman; William G Kerr
Journal:  J Immunol       Date:  2010-03-03       Impact factor: 5.422

Review 7.  Many mechanisms mediating mobilization: an alliterative review.

Authors:  Jonathan Hoggatt; Louis M Pelus
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

8.  SHIP is required for a functional hematopoietic stem cell niche.

Authors:  Amy L Hazen; Michelle J Smith; Caroline Desponts; Oliver Winter; Katrin Moser; William G Kerr
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

9.  Targeting of the GTPase Irgm1 to the phagosomal membrane via PtdIns(3,4)P(2) and PtdIns(3,4,5)P(3) promotes immunity to mycobacteria.

Authors:  Sangeeta Tiwari; Han-Pil Choi; Takeshi Matsuzawa; Marc Pypaert; John D MacMicking
Journal:  Nat Immunol       Date:  2009-08       Impact factor: 25.606

10.  The inositol polyphosphate 5-phosphatase ship is a crucial negative regulator of B cell antigen receptor signaling.

Authors:  Q Liu; A J Oliveira-Dos-Santos; S Mariathasan; D Bouchard; J Jones; R Sarao; I Kozieradzki; P S Ohashi; J M Penninger; D J Dumont
Journal:  J Exp Med       Date:  1998-10-05       Impact factor: 14.307

View more
  10 in total

1.  Granulocyte-CSF links destructive inflammation and comorbidities in obstructive lung disease.

Authors:  Evelyn Tsantikos; Maverick Lau; Cassandra Mn Castelino; Mhairi J Maxwell; Samantha L Passey; Michelle J Hansen; Narelle E McGregor; Natalie A Sims; Daniel P Steinfort; Louis B Irving; Gary P Anderson; Margaret L Hibbs
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

2.  Loss of lipid phosphatase SHIP1 promotes macrophage differentiation through suppression of dendritic cell differentiation.

Authors:  Eui Young So; Changqi Sun; Anthony M Reginato; Patrycia M Dubielecka; Toru Ouchi; Olin D Liang
Journal:  Cancer Biol Ther       Date:  2018-10-02       Impact factor: 4.742

3.  SHIP-1, a target of miR-155, regulates endothelial cell responses in lung fibrosis.

Authors:  Haiying Tang; Jingwei Mao; Xujun Ye; Fengrui Zhang; William G Kerr; Tao Zheng; Zhou Zhu
Journal:  FASEB J       Date:  2019-12-12       Impact factor: 5.191

4.  Analysis of the human monocyte-derived macrophage transcriptome and response to lipopolysaccharide provides new insights into genetic aetiology of inflammatory bowel disease.

Authors:  J Kenneth Baillie; Erik Arner; Carsten Daub; Michiel De Hoon; Masayoshi Itoh; Hideya Kawaji; Timo Lassmann; Piero Carninci; Alistair R R Forrest; Yoshihide Hayashizaki; Geoffrey J Faulkner; Christine A Wells; Michael Rehli; Paul Pavli; Kim M Summers; David A Hume
Journal:  PLoS Genet       Date:  2017-03-06       Impact factor: 5.917

5.  Selective deletion of SHIP-1 in hematopoietic cells in mice leads to severe lung inflammation involving ILC2 cells.

Authors:  Xujun Ye; Fengrui Zhang; Li Zhou; Yadong Wei; Li Zhang; Lihui Wang; Haiying Tang; Zi Chen; William G Kerr; Tao Zheng; Zhou Zhu
Journal:  Sci Rep       Date:  2021-04-28       Impact factor: 4.379

6.  SHIP-1 Couples to the Dectin-1 hemITAM and Selectively Modulates Reactive Oxygen Species Production in Dendritic Cells in Response to Candida albicans.

Authors:  Noelia Blanco-Menéndez; Carlos Del Fresno; Sandra Fernandes; Enrique Calvo; Ruth Conde-Garrosa; William G Kerr; David Sancho
Journal:  J Immunol       Date:  2015-09-28       Impact factor: 5.422

Review 7.  Harnessing murine models of Crohn's disease ileitis to advance concepts of pathophysiology and treatment.

Authors:  Lida Iliopoulou; George Kollias
Journal:  Mucosal Immunol       Date:  2021-07-27       Impact factor: 7.313

8.  Analysis of SHIP1 expression and activity in Crohn's disease patients.

Authors:  Rajesh Somasundaram; Sandra Fernandes; Jasper J Deuring; Colin de Haar; Ernst J Kuipers; Lauran Vogelaar; Frank A Middleton; C Janneke van der Woude; Maikel P Peppelenbosch; William G Kerr; Gwenny M Fuhler
Journal:  PLoS One       Date:  2017-08-02       Impact factor: 3.240

Review 9.  Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn's Disease-Like Ileitis: What is the Right Model?

Authors:  Fabio Cominelli; Kristen O Arseneau; Alexander Rodriguez-Palacios; Theresa T Pizarro
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2017-03-06

10.  Lyn prevents aberrant inflammatory responses to Pseudomonas infection in mammalian systems by repressing a SHIP-1-associated signaling cluster.

Authors:  Rongpeng Li; Lizhu Fang; Qinqin Pu; Ping Lin; Austin Hoggarth; Huang Huang; Xuefeng Li; Guoping Li; Min Wu
Journal:  Signal Transduct Target Ther       Date:  2016-12-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.